Alzheimer's Prevention Research Study

Researchers at the Institute for Molecular Medicine are partnering with individuals diagnosed with mild cognitive impairment due to Alzheimer's disease to evaluate how immunotherapy can help. Join our compensated study today.

Fast Facts

mild cognitive impairment

have a reliable study partner

60-85 years old

Compensation Provided

Study Background

Did you know immunotherapy is one of the most promising therapeutic strategies for Alzheimer’s disease prevention?

Alzheimer’s disease (AD) is currently an incurable neurodegenerative disorder and the leading form of age-related dementia. It is characterized by progressive impairment of memory and cognitive functions.

This research study will investigate a DNA-based vaccine to study prevention of AD. Individuals 60-85 years old who have been diagnosed with mild cognitive impairment may be eligible to join with a study partner.

Your participation in this research study may help researchers improve treatment approaches to prevent AD. Further research today and join our compensated study!

This study is supported by a grant from the National Institute of Aging, a division of the National Institute of Health, to the study sponsor – the Institute of Molecular  Medicine (Huntington Beach, CA) and its collaborators at the University of California, Irvine and the University of Southern California. This research is supported by the National Institute on Aging (NIA) division of the U.S. National Institutes of Health (NIH) under grant number R01-AG074983.

Additional Information

The main goal of this study is to evaluate the safety of AV-1959D vaccine in subjects with early Alzheimer’s disease.

You may qualify for this study if you meet the following criteria.

Key Criteria:

  • 60-85 years old
  • Diagnosed with mild cognitive impairment due to Alzheimer’s disease
  • No uncontrolled medical conditions
  • No prior administration of any vaccine or antibody for Alzheimer’s disease
  • Have a reliable study partner (a trusted family member, friend, or caregiver) who will accompany you to all clinic visits during the study, and have sufficient contact with you to be able to provide accurate information about your memory and thinking skills and daily function

Screening: If you and your study partner decide to participate in the study, you will be asked to attend two or more screening visits within 90 days of enrollment.

Treatment: If eligible, you will be asked to return to the clinic on Days 1, 8, 15, and 43 of the study. The vaccine will be administered on Days 1, 15, and 43. The study treatment day visits will take approximately four hours.

Follow-up: After receiving the last study treatment on Day 43, you will be asked to return to the clinic for follow-up visits on Days 57, 85, 141, and 197. These follow-up visits should take approximately three hours.

Overall, the study includes about 11 visits to the clinic, including screening visits, over a period of about 40 weeks.

This study is being conducted at 6 different sites.

  • Banner Alzheimer’s Institute (Phoenix, AZ)
  • Global Medical Institutes / Princeton Medical Institute (Princeton, NJ)
  • Hoag Memorial Hospital Presbyterian (Newport Beach, CA)
  • Alzheimer’s Research and Treatment Center (Wellington, FL)
  • Department of Psychiatry and Behavioral Neurosciences, University of South Florida (Tampa, FL)
  • Accel Research Sites: Neurostudies (Decatur, GA)

Depending on the treatment site, you may be compensated between $25-$100 per study visit for your time.

There is no cost for you to participate in the study.